All Stories

  1. Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
  2. P-374 Stratifying multiple myeloma patients for personalized therapy based on TP53 mutation, deletion, and drug response profiles
  3. Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
  4. Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  5. Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  6. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  7. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  8. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  9. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  10. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  11. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  12. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
  13. Implementing a functional precision medicine tumor board for acute myeloid leukemia
  14. Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature
  15. Converging molecular evolution in acute myeloid leukaemia
  16. Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results
  17. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease
  18. Does breast carcinoma belong to the Lynch syndrome tumor spectrum? – Somatic mutational profiles vs. ovarian and colorectal carcinomas
  19. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
  20. Somatic mutations and T-cell clonality in patients with immunodeficiency
  21. Somatic Mutations in Clonally Expanded T-lymphocytes in Patients with Chronic Graft-Versus-Host Disease
  22. Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling
  23. Epidemiological, clinical and molecular characterization of Lynch‐like syndrome: A population‐based study
  24. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
  25. Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells
  26. Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency
  27. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells
  28. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas
  29. Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine
  30. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
  31. Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations
  32. 3Precision systems medicine in urological Tumors – Molecular profiling and functional testing
  33. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
  34. Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells
  35. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis
  36. Identification of precision treatment strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity testing
  37. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer
  38. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
  39. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia
  40. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia
  41. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
  42. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
  43. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
  44. A6.02 Somatic mutations in clonally expanded CD8+T cells in patients with newly diagnosed rheumatoid arthritis
  45. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers
  46. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia
  47. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3
  48. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing
  49. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
  50. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation
  51. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
  52. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
  53. SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
  54. Comparison of solution-based exome capture methods for next generation sequencing